Pfizer Inc. Stock
€20.51
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Pfizer
sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.
Financials
News
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income-seeking
Pfizer Stock: Billion-Dollar Chinese Cancer Drug Deal
Pharmaceutical giant Pfizer is making significant strategic moves in oncology, investing up to $6 billion in a licensing deal with Chinese biotech firm 3SBio. The agreement centers on SSGJ-707, a
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green in 2025 as of the Apr. 21 close. Shares were down
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in
Pfizer Stock: Probe Into COVID Vaccine Timing Claims
Pfizer shares are facing significant pressure following reports that Manhattan federal prosecutors are investigating serious allegations. The inquiry centers on claims made by British pharmaceutical
Pfizer Stock: Company Sells Entire Haleon Stake
Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per
Pfizer Stock: Shares Drop Despite Cancer Drug Progress
Pfizer's stock fell 1.7% to $26.20 in Tuesday afternoon trading on the New York Stock Exchange, despite the company announcing promising results from a key clinical trial. The decline came amid
Pfizer Stock: Nearing 52-Week Lows Amid Challenges
Pfizer's stock currently faces a challenging market position, trading precariously close to its 52-week lows. The shares recently showed minimal recovery, rising just 0.2 percent to $25.99 in New
Pfizer Stock: Court Ruling Clouds Positive Momentum
Pfizer shares gained 0.9 percent on Wednesday in New York trading, closing at $25.98 after reaching an intraday high of $26.17. Investor interest remained strong with over one million shares
Pfizer Stock: Cancer Drug Study Shows Promising Results
Pfizer and Astellas Pharma have achieved a significant breakthrough in advanced bladder cancer treatment, demonstrating remarkable success with their combination therapy of PADCEV and KEYTRUDA. The
Pfizer Stock: Quarterly Results Show Strong Recovery Signs
Pfizer's recent quarterly performance demonstrates a significant turnaround, with revenues surging nearly 25% to reach $17.76 billion. The pharmaceutical giant has shown remarkable improvement in
Pfizer Stock: Q4 Surge Despite Market Dip
Pfizer's stock experienced a modest decline of 0.8% to $26.24 in Thursday's New York trading session, yet the pharmaceutical giant's underlying performance tells a more compelling story. The company
Pfizer Stock: AI Partnership Drives Strategic Transformation
Pharmaceutical giant Pfizer is embarking on a significant strategic shift with a heightened focus on artificial intelligence through a multi-year collaboration with technology firm Data4Cure. This
Pfizer Stock: Cancer Drug Study Shows Promising Results
Pfizer's recent breakthrough in cancer research is painting a promising picture for the pharmaceutical giant, despite its stock experiencing a slight dip of 0.9% to $26.27. The company has achieved
Top 3 Stocks Seeing a Spike in Call Option Volume
Volume is what drives the entire market, and that is a fact that often gets lost in the sea of indicators, patterns, and trend lines that dominate today’s concept of analysis. However, most
2 Top Stocks to Buy With Less Than $30
Though wealthy and successful investors garner much attention on Wall Street, equity markets are accessible to the average person. That's one of the great things about investing in stocks. Even with
Why I Just Bought More of This Beaten-Down 7%-Yielding Dividend Stock
Pick a time frame -- year to date, last 12 months, last three years, last five years, or last 10 years. Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the
Create a Portfolio of Passive Income: 3 High-Yielding Dividend Stocks That Pay More Than 5%
Dividend income offers a great way to strengthen your overall financial position. It can potentially make you less dependent on the income you earn from a job, maybe even allowing you to work less
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
How would you like to get paid every quarter (and sometimes every month) to own a stock? That's exactly what happens when you invest in dividend stocks. Sometimes, the amount you are paid to own
Should You Buy Pfizer Stock Right Now?
If you have an opening in your portfolio for a great stock with solid growth potential and perhaps even a respectable dividend yield, you would do well to give Pfizer (NYSE: PFE) some serious
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Should you chase high yields from slow-growing businesses or invest in lower-yield providers with more
Why BioNTech Stock Soared Today
BioNTech (NASDAQ: BNTX), one of the companies made famous for its role developing vaccines with Pfizer (NYSE: PFE) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news
Terrible News for Pfizer Stock Investors
The past three years have been challenging for Pfizer (NYSE: PFE). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022
Is Pfizer Stock a Buy After This $1.25 Billion Investment?
Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.
However
Down 63%, Should You Buy the Dip on Pfizer?
It's been a tough go for Pfizer (NYSE: PFE). Shares of the pharmaceutical giant are down over 60% from their highs, a multi-year slide since pandemic-related sales peaked a few years ago. But that's